Why Is Palantir Stock Falling? PLTR Slides 6.1% on NHS Scrutiny and Competition Concerns

Key Takeaways

• Palantir stock closed 6.1% lower at $124.57 on July 22, extending an intraday decline that had initially been around 5%.
• Scrutiny of performance claims linked to Palantir’s NHS data platform and discussion of a popular open-source alternative weighed on sentiment.
• The wider weakness in software stocks and caution before Palantir’s August 3 earnings report amplified the sell-off.

Several Pressure Points Hit Palantir Stock at Once

Palantir Technologies (NASDAQ: PLTR) fell sharply on Wednesday as investors responded to a combination of regulatory, competitive and market-wide concerns.

PLTR stock closed at $124.57, down 6.1% from the previous session. The shares traded between $123.45 and $132.35 during the day, with volume reaching approximately 38.6 million shares. The final decline was therefore larger than the roughly 5% drop recorded earlier in the session.

There was no single company announcement explaining the entire move. Instead, the decline appeared to reflect a broader repricing of risk as investors considered fresh scrutiny surrounding Palantir’s work with the UK National Health Service, growing discussion of open-source intelligence software and the company’s demanding valuation.

UK Watchdog Questions NHS Platform Performance Claims

One of the main concerns involved the way NHS England communicated performance data related to the Federated Data Platform, or FDP.

The platform, which is built around Palantir’s Foundry technology, connects information from different parts of the NHS to support hospital capacity planning, waiting-list management and patient discharge decisions.

NHS England had previously highlighted figures suggesting that organisations using the platform completed more operations and reduced discharge delays. However, the UK’s Office for Statistics Regulation examined whether those statistics were presented with sufficient context.

NHS England subsequently added a caveat explaining that the figures could not establish a direct cause-and-effect relationship because other variables had not been controlled. An independent academic assessment of the platform is also expected to provide a more detailed evaluation.

The development does not mean Palantir has lost the NHS contract, nor does it prove that the platform is ineffective. Nevertheless, the scrutiny could make it harder for the company and NHS England to rely on headline performance figures when demonstrating the project’s value.

For investors, that matters because large government contracts are an important part of Palantir’s long-term growth narrative.

Greater Manchester Highlights a Domestic Alternative

The debate intensified after Greater Manchester’s integrated care board was highlighted as an example of an NHS organisation operating without Palantir’s platform.

Dr Devan Moodley, CEO of Health Connect Global, wrote that Greater Manchester had developed its own data infrastructure with British universities, NHS clinicians and domestic technology companies. The region remains the only integrated care board in England to have declined the Palantir-built FDP.

This does not immediately threaten Palantir’s existing NHS revenue. However, it strengthens the argument that public-sector organisations could consider locally developed alternatives when future contracts are awarded or renewed.

The issue is particularly sensitive because healthcare data contracts involve privacy, digital sovereignty and dependence on overseas technology providers. Continued political or regulatory scrutiny may therefore affect expectations for Palantir’s future UK expansion.

Open-Source World Monitor Raises Competition Questions

Palantir shares also came under pressure as traders discussed World Monitor, an open-source global intelligence dashboard available through GitHub.

The software combines AI-powered news aggregation, geopolitical monitoring and infrastructure tracking in a single interface. Its GitHub repository has attracted more than 69,000 stars and 10,000 forks, indicating strong interest among developers.

World Monitor is not a direct replacement for Palantir’s full enterprise offering. Palantir provides data integration, security, governance and operational software for large companies and government agencies, often through complex multi-year deployments.

However, the rise of lower-cost and open-source tools could still influence investor perceptions. If customers can reproduce some intelligence-monitoring functions without purchasing an extensive proprietary platform, Palantir may face greater pressure to demonstrate why its technology commands premium pricing.

That concern carries more weight because PLTR trades at a high valuation. Based on its July 22 closing price, the company’s trailing price-to-earnings ratio remained around 140. Highly valued stocks are often more sensitive to even early signs of stronger competition or slower growth.

Wider Software Sell-Off Amplifies the Decline

Palantir’s fall also occurred during a weak session for the broader software industry.

The Nasdaq Composite declined 0.57% on July 22, while a software-sector index suffered a substantially larger drop. Semiconductor stocks performed better, suggesting investors were becoming more selective about which parts of the AI market they were willing to support.

The S&P 500 slipped 0.14%, while the Dow Jones Industrial Average was nearly unchanged. Rising oil prices and uncertainty ahead of major technology earnings added to the cautious market mood.

Palantir therefore faced both company-specific pressure and a broader rotation away from expensive software stocks. That combination helps explain why its decline was considerably larger than the drop in the major US indices.

August 3 Earnings Put Growth and Valuation in Focus

Attention is now turning to Palantir’s second-quarter results, scheduled for release after the US market closes on August 3.

The company has guided for quarterly revenue of between $1.797 billion and $1.801 billion. Market estimates point to adjusted earnings of approximately $0.33 per share.

Palantir entered the quarter with strong operating momentum. First-quarter revenue increased 85% year on year to approximately $1.63 billion, while US revenue more than doubled. Management also raised its full-year outlook as demand for its Artificial Intelligence Platform continued to expand.

However, those results have created high expectations. Investors will be looking for evidence that Palantir can sustain rapid commercial growth while protecting margins and defending its position against both established software companies and newer AI tools.

Any slowdown in customer additions, contract values or US commercial revenue could place further pressure on the valuation. Conversely, stronger-than-expected results or guidance could ease concerns surrounding competition and government-contract uncertainty.

PLTR Stock Levels to Watch

Palantir’s July 22 low of $123.45 represents the nearest short-term support area. A sustained move below that level could shift attention towards the stock’s June low and 52-week low near $106.37.

Initial resistance sits around $132 to $133, covering the previous closing price and the upper end of Wednesday’s trading range. PLTR may need to recover that area before the immediate technical pressure begins to ease.

At $124.57, Palantir stock is approximately 40% below its 52-week high of $207.52. The size of that decline shows how investor sentiment towards highly valued AI software companies has changed, despite Palantir’s continued revenue growth.

The July 22 sell-off appears to be driven primarily by a combination of regulatory uncertainty, competition concerns, valuation sensitivity and wider software-sector weakness—not by a newly announced contract cancellation or reduction in Palantir’s financial guidance.